CHDR1514 - Data Repository.xlsx

Data from the CHDR1514 clinical trial titled "A randomized, double-blind, placebo-controlled study to investigate the effects of recombinant human erythropoietin (NeoRecormon) on cycling performance and the occurrence of adverse events in well-trained cyclists.". In the datafile each row is one measurement. Lactate values per subject, per maximal exercise test, per exercise intensity is reported. Average power output for the submaximal exercise test (Time Trial) and road race are also reported.<br><br>Legend:<br>Protocol = Protocol number<br>SubjectNr = Subject number<br>ProtTime = Protocol time (zero point is first dosing)<br>ExpDelta = Expected delta time in minutes (zero point is first dosing)<br>Activity = Performed activity<br>Activity_Notes_N = Notes to the activity<br>Parameter = Measured parameter<br>Parameter_description = Description of the parameter<br>Value = Measured value<br>Unit = Unit of the value<br>Parameter_Notes_N = Notes to the parameter<br>LactMax = Lactate measurements belonging to maximal exercise test<br>ExercSubmax = Submaximal exercise test, or Time trial test<br>Race = Road race<br><br>